Key facts
- Notable investors include Lapam Capital, Guangzhou Science City Venture Capital, Hejun Group, Heyu Pinjing Investment Management, Sichuan Xingyong Private Equity Fund Management.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Danlan Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Danlan Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Danlan Biotechnology
Provider of early tumor diagnostic technologies intended for clinical use. The company's offerings include liquid suspension chip based diagnostic assays, serum autoantibody profiling tools, early screening test kits for lung, esophageal, and ovarian cancers, and GMP grade production, enabling healthcare institutions to improve early cancer detection accuracy and support timely clinical decision making.
- Sector
- Healthcare
- HQ
- Guangzhou, China
- Founded
- 2015
- Website
- danlanbio.com/
- Ownership
- Privately Held (backing)
Danlan Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Danlan Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Danlan Biotechnology in its N-PORT filings yet. We sweep new filings monthly.